Original Article

Managing in-hospital quality improvement: an importance-performance analysis to set priorities for STEMI care

Daan Aeyels, MSc[1], Deborah Seys, PhD[1], Peter R Sinnaeve, MD, PhD[2], Marc J Claeys, MD, PhD[3], Sofie Gevaert, MD, PhD[4], Danny Schoors, MD, PhD[5], Walter Sermeus, PhD[1], Massimiliano Panella, MD, PhD[6], Luk Bruyneel, PhD[1,7], Kris Vanhaecht, PhD[1,7]

[1] Leuven Institute for Healthcare Policy, University of Leuven, Leuven, Belgium;

[2] Department of Cardiology, University Hospitals Leuven, Belgium;

[3] Department of Cardiology, Antwerp University Hospital, Edegem, Belgium;

[4] Department of Cardiology, University Hospital Ghent, Ghent, Belgium;

[5] Department of Cardiology, University Hospitals Brussels, Jette, Belgium

[6] Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Vercelli, Italy;

[7] Department of Quality Management, University Hospitals Leuven, Leuven, Belgium

Corresponding author

Daan Aeyels, Leuven Institute for Healthcare Policy, University of Leuven, Kapucijnenvoer 35, B-3000 Leuven, Belgium. Telephone: +32 16 373362; Fax: +32 16 336970 E-mail: daan.aeyels@kuleuven.be

Key words:

Quality Improvement; Evidence Based Medicine; Importance-Performance Analysis; Acute Coronary Syndrome

Introduction

Closing the delivery gap between evidence and patient care is challenging healthcare providers. In comprehensive and complex care processes, a complete redesign of practice may be needed to achieve optimal care.[1] Such fundamental change often surpasses organizational capacity. Healthcare professionals and their organizations struggle with the scope and pace of broad and systematic quality improvement interventions. The cumulative effect of multiple and simultaneous improvement efforts lead to change fatigue, an increase in workload and burn-out, specifically in nursing.[2, 3] As a result, broad quality improvement interventions deal with resistance, incomplete implementation or failure. To address these challenges, improvement strategies like Plan Do Study Act (PDSA) and the Institute for Healthcare Improvement (IHI)'s Model for Improvement demand to set specific improvement priorities.[4]

Variation in performance between hospitals complicates priority setting. If performance varies across a broad range of key interventions, it opposes the use of a unique set of priorities in a multicentre improvement project. This reinforces the case for tailored quality improvement interventions to address the underlying factors of each individual hospital's performance. However, there is a lack of evidence on how to tailor priorities in quality improvement interventions.[5]

ST-elevation Myocardial Infarction (STEMI) offers a relevant case to illustrate challenges in priority setting in a multicentre improvement effort. Clinical care for

STEMI patients varies persistently within and between hospitals. Differences in patient case-mix do not justify the observed variation. Rather, variation is largely driven by a fluctuating and complex process involving a wide range of disciplines and clinical departments under vast time pressure.[6] Nurses play a critical role in streamlining the complex STEMI care process to achieve timely reperfusion and secondary prevention.[7, 8] Guidelines and extensive sets of data elements are available to guide this improvement. Yet, the implementation of guidelines is a serious problem requiring urgent improvement to ensure patients receive optimal evidence-based care.[9]

Importance-performance analysis prioritizes key interventions by depicting experts' opinion on importance of a key intervention against the performance on this key intervention. This technique identifies improvement priorities by (graphically) exemplifying disparity between importance and performance. Besides recognizing performance as a factor in priority setting, importance-performance analysis can handle input from multidisciplinary expertise.[10] Such approach might result in a clear set of improvement priorities for STEMI.

The aim of this study is to identify quality improvement priorities for in-hospital STEMI care through an importance-performance analysis that links multidisciplinary expert consensus on importance of key interventions with hospital performance levels.

Methods

Design, setting & sample

We performed a cross-sectional multicentre study of adult STEMI patients hospitalized between 2013 and 2014. Fifteen hospitals (response rate 93.7%) were recruited were recruited for the CP4ACS study through the Belgian-Dutch Care Pathway Network, a network of health care organizations in Belgium sharing knowledge on care pathway methodology. Although we initially aimed to include only ten hospitals, fifteen hospitals agreed to participate and each retrospectively recruited 20 consecutively admitted STEMI patients (n=300). Adult patients admitted within 24 hours after symptom onset and eligible for reperfusion strategy (whether thrombolysis or percutaneous coronary intervention (PCI) according to the European Society of Cardiology (ESC) STEMI guidelines were included.[11] Patients with severe concomitant disease resulting in deviations from guideline-recommended care were excluded.

Assessing importance and performance

To assess importance of key interventions, an initial set of 27 interventions was identified through a structured literature review of international STEMI guidelines and improvement articles. Subsequently, 23 key interventions were validated in a RAND Delphi-survey in two rounds. First, a multidisciplinary panel of 34 (76% response rate) cardiologists, nurse managers and quality managers appraised key interventions

individually. After receiving feedback, 32 experts (71% response rate) openly discussed items with a content validity index (CVI) above 75% in a consensus meeting and validated the final set of key interventions. CVIs were computed as the proportion of experts that rated a STEMI key intervention as important to quality improvement between 7 and 9 on a 9-point Likert scale. At the outset of the study, the cut-point to consider items as important to STEMI quality improvement was set at 75%.[12]

Adherence to STEMI guidelines was measured by reviewing patient records using a structured audit tool. The audit tool discriminated between documentation and performance of key interventions. Key interventions were considered non-documented whenever information on performance of the intervention was missing or ambiguous. Variables were reported as non-performed when the patient record explicitly stated the absence of the intervention. Performance is reported as a proportion both at patient and hospital level. Our patient level measure reflects the proportion of relevant key interventions performed for that particular patient. Our hospital level measure aggregates the proportion of patients for whom relevant key interventions were performed. Data were collected and coded by a local study coordinator. The central study coordinator monitored data quality by verifying a random 10% sample of included patients. The participating hospitals validated the results.

We created an importance-performance matrix by ranking key interventions on CVI and plotting their corresponding performance levels. A 75% cut-point for both importance

and performance resulted in four quadrants. The upper right 'quadrant 1' includes key interventions for which both importance as well as performance levels were high. Hospitals should at least maintain performance levels of key interventions in 'quadrant 1'. The upper-left 'quadrant 2' captures priorities for improvement, i.e. their importance is highly valued by experts whilst hospital performance is low. The lower-left 'quadrant 3' includes low priority key interventions, i.e. expert-rated importance as well as hospital performance is low. The lower-right 'quadrant 4' represents possible overuse, i.e. there is no consensus among experts on the relevance of these key interventions to quality improvement, whilst hospital performance is high.[10]

To illustrate variation between hospitals, we constructed a heat-map that ranked important key interventions (CVI >75%) based on the number of hospitals for which the key intervention was an improvement priority (performance ≤75%).

Statistical analysis

Timely reperfusion was calculated as the interval between first medical contact to primary PCI (defined as wire passage into the culprit artery) and analysed considering the need for transfer (≤120 minutes in case of transfer; all others ≤90 minutes).[11]

For each key intervention, the median and interquartile range (IQR) were calculated to describe variation within and between hospitals. Variation in performance between hospitals was assessed by a Kruskal-Wallis test for skewed data distributions within

independent samples. Analyses were performed in IBM SPSS version 24.0 and R using packages easyGgplot2 and ggplot2.

Ethical considerations

This study is part of the Care Pathways for Acute Coronary Syndrome (CP4ACS) quality improvement program registered at ClinicalTrials.gov (NCT02961777). Ethical approval was obtained from the ethical committee of the University Hospitals of Leuven (ML9733). We confirm that this study conforms with the principles outlined in the Declaration of Helsinki.[13]

Results

Patient and hospital characteristics.

The characteristics of included patients (n=300) are summarized in Table 1. The mean age upon admission was 64.3 years. Three quarters (74.7%) of patients were male. Almost half of the patients (44.3%) were directly admitted to a PCI capable hospital. A vast majority (96.7%) received reperfusion therapy, 99.3% of which through primary PCI. Nine of 15 participating hospitals had 24/7 PCI capacity, all but one of which with an annual PCI volume over 400. Ten served as a cardiology training centre and four were academic hospitals. [Insert Table 1 here.]

Documentation of STEMI care differed per key intervention and per hospital. The documentation of five important key interventions was suboptimal: cardiovascular history (64.2%), cardiac rehabilitation (58.1%), nutritional advice (57.7%), smoking cessation for active smokers (49.2%) and home medication upon admission (42.2%). PCI and post-PCI key interventions were documented in >83% of patients, discharge medication was documented in >95% of patients.

Priorities in STEMI performance

An overview of STEMI key interventions and descriptive statistics on importance and performance is provided in Table 2. Figure 1 shows the importance-performance analysis. The 13 of 23 (56.5%) key interventions in 'quadrant 1' were considered important by the expert panel (CVI ≥75%) and were performed in >75% of patients. PCI was used in 96.3% of patients as a primary reperfusion therapy. Post-PCI left ventricular evaluation, electrocardiogram (ECG)-monitoring, and discharge medication were performed in >75% of patients. Aspirin, statin and P2Y12-inhibitors reached performance levels above 95%. Apart from aspirin (72.1%), all important (CVI ≥75%) peri-procedural medication interventions were performed in >75% of patients.

Seven of 23 (30.4%) key interventions were considered a priority for STEMI quality improvement ('quadrant 2'). Timely reperfusion, stratified by transfer status, was provided for 60.7% of patients. Overall, lifestyle interventions were performed for

46.4% of patients: cardiac rehabilitation (52.1%), nutritional advice (49.6%) and smoking cessation in active smokers (37.4%).

'Quadrants 3' and 'Quadrant 4' illustrate the performance of three key interventions considered less important (CVI <75%) to quality improvement. Guideline recommended blood tests were performed for 76.8% of included patients. Assessment of Killip class was performed for 72.3% and peri-procedural opioids were administered for 38.3% of patients. [Insert Table 2 and Figure 1 here.]

Performance priorities vary between hospitals

Figure 2 illustrates the variation in performance priorities per hospital. The hospitals were ranked by the number of important key interventions performed in ≤75% of patients within the hospital. Between hospitals, the number of performance priorities ranged from one to 11 STEMI key interventions. Six key interventions were underperformed in ten or more (66.7%) of the participating hospitals.

Data show significant variation in performance levels between hospitals. Except for performance of peri-procedural P2Y12 inhibitor, P2Y12-inhibitor at discharge and primary PCI, between-hospital variation on performance was significant for individual key interventions ($p<0.001$). Variation was small for discharge medication (IQR 5.1-12.7%). Variation was large for interventions on assessment of cardiovascular risk and antecedents (IQR 12.5-63.8%), lifestyle interventions (IQR 25.1%-63.4%) and timely

performance of reperfusion therapy (IQR 38.0%). Only one patient received all key interventions needed to provide optimal STEMI care. Remarkably, for every individual key intervention, at least one hospital attained performance levels above 90%. [Insert Figure 2 here.]

Discussion

This importance-performance analysis set priorities that serve in development of effective quality improvement interventions for STEMI care. Our study resulted in important observations. First, documentation of care was suboptimal in five of 23 key interventions. Second, our analysis identified seven of 23 key interventions as overall performance priorities. These priorities relate to timely reperfusion by PCI, risk assessment, and secondary prevention. Third, we observed significant variation in performance of key interventions between hospitals. Our heat-map provided more depth by showing performance levels per hospital and per key intervention. This revealed important differences in the nature, the number and the order of improvement priorities between hospitals.

These differences in performance refute one-size-fits-all improvement interventions and calls for a tailored approach. The identified priorities may serve as a menu to tailor improvement efforts and focus on distinct care processes. Such focus makes improvement efforts more tangible and manageable compared to broad, undirected interventions. Vice versa, an overly tight focus may result in a loss of attention for those

processes that are not under focus. A combination of continued and incremental improvement offsets the downside of too narrowly focused improvement efforts.[14] Considering at least one hospital performs well on each of the key interventions, transfer of best practices through collaboratives is possible. Collaborative and incremental quality improvement strategies have been applied by the Institute for Healthcare Improvement and the American College of Cardiology, albeit without offering clear guidance on how to set priorities.[15, 16]

Our focus on care processes is appropriate for quality improvement interventions targeting clinical practice variation. Improvement of care processes is also most likely to increase patient experience and has been associated with significant decreases in in-hospital mortality.[17] Working with care processes has the advantage that they can be addressed directly by clinicians, require little risk adjustment and limited sample size. Process measures also allow for easy data extraction, rapid feedback and clear goal setting.[18] A major hurdle when dealing with complex care processes is the large number of key interventions needed to achieve optimal care.[19] A focus on a small set of evidence-based key interventions has led to significantly better care.[20]

The proportion of patients receiving timely coronary reperfusion is comparable to other European studies and conform targets set by international guidelines.[21] Improvement of reperfusion delays will lead to reduced mortality and morbidity both in the short and long term. There is sound evidence on effective improvement strategies to reduce

reperfusion delays.[22] Performance of necessary lifestyle changes in our study is comparable to other European research.[23] Performance on discharge medication was similar to performance levels in America and Europe, except for angiotensin converting enzyme (ACE) or angiotensin receptor blocker (ARB)-inhibitors and beta-blocker; which were lower than American levels.[24] Lifestyle interventions and guideline recommended discharge medication are cost-effective and have a significant effect on long-term outcomes.

Improving performance requires joint efforts by a multidisciplinary team and transcends the boundaries of the hospital. Proper risk stratification is a prerequisite for improving STEMI care management. Cardiovascular risk assessment is part of the early triage and diagnosis process with special value in atypical presentations. Better cardiovascular risk assessment may lead to better outcomes through effective triage and timely reperfusion. Nurse practitioners have a direct role in improvement of risk stratification and timely reperfusion.[25, 26] Better risk assessment increases inclusion in secondary prevention and rehabilitation programs targeting lifestyle changes and pharmaceutical therapy. Furthermore, an updated and shared STEMI protocol, use of checklists, and oral and written discharge instructions could improve documentation and prescription of discharge medication.[27]

Our distinction between documentation and performance of care was important because of the differing solutions to both problems. In addition, documenting care has

previously been associated to better performance of care processes.[28] Although there is no certainty about the performance of undocumented care, some circumstances may explain suboptimal documentation without compromising performance: In the acute phase of STEMI care, the provision of life-saving care may get priority over its documentation. Likewise, in the post-acute phase, hospitals may no longer bare responsibility for documentation of STEMI care as the patient may have been transferred back to the referring hospital or primary care. In this case, the reported result may be an underestimation of performance.

Some methodological limitations apply. First, to determine importance levels, we pooled multidisciplinary knowledge and experience. The deliberate involvement of nurses expressed their increasing role in organisation and improvement of care processes that contribute to improved patient care.[29] We did not involve patients in the expert panel to select and validate STEMI key interventions. Patients have preferences on structural, process and outcomes of healthcare and patient involvement could influence priorities for quality improvement.[30] Scarce evidence indicates that patient involvement does shift priorities from technical aspects of clinical care towards idiosyncratic aspects like timely access to care, self-care support and patient participation in clinical decision-making.[31] While patient involvement might influence priority setting for quality improvement, effective patient involvement requires time and dedicated resources to overcome limited clinical knowledge and unbalanced representation. Such efforts exceeded the scope of our study.

Second, our choice of the 75% cut-off score to visualize the delivery gap and prioritize improvement opportunities was pragmatic. Guidelines on Delphi research and previous research in cardiology justify a 75% threshold on importance. The basis for a 75% cut-off score on performance levels is less straightforward. Therefore, we evaluated the impact of our cut-points on priorities by shifting it between 50% and 90%. The ranking of priorities altered when performance cut-points were below 60% or above 90%. Also, between-hospital performance variation could complicate priority setting as key interventions may cross quadrant borders and thus complicate priority setting.

Conclusions

Our study related the importance of key interventions for in-hospital STEMI care to their performance levels. Proper risk assessment, timely reperfusion and secondary prevention were identified as overall priority in STEMI quality improvement interventions. Better performance on these care processes has been associated with better outcomes. Furthermore, significant between-hospital variation on performance revealed the need to tailor improvement interventions to hospital-specific improvement priorities.

In healthcare, importance-performance analysis is immature and additional efforts are needed to deepen some methodological aspects. Our study revealed ambiguities about setting the cut-points that discriminate between priorities. Given the between-hospital differences in performance, tailored cut-points seem an interesting element to explore

further. Despite this immaturity, we emphasize the need for a broader and widespread use of importance-analysis as it offers necessary support to make improvement interventions more effective.

Implications for practice

- Better documentation is prerequisite for improvement
- Objective priorities focus improvement efforts.
- Tailored improvement addresses variation in priorities
- Nurses have an important role in performance improvement

Acknowledgements

We thank the members of the Belgian-Dutch Care Pathway Network for their participation in this research. We thank the Belgian Interdisciplinary Working Group on Acute Cardiology for the collaboration on the Belgian STEMI register. This work was supported by the European Pathway Association. The European Pathway Association thanks AstraZeneca for the provision of an unrestricted educational grant to the CP4ACS project. AstraZeneca had no role in the design, data collection, analysis, interpretation of data, writing of the report, or decision to submit the report for publication.

References

1. Nelson EC, Batalden PB and Godfrey MM. *Quality by design: a clinical microsystems approach*. John Wiley & Sons, 2011.
2. Chassin MR and Loeb JM. High-reliability health care: getting there from here. *Milbank Q*. 2013; 91: 459-90.
3. White M, Wells JS and Butterworth T. The impact of a large-scale quality improvement programme on work engagement: preliminary results from a national cross-sectional-survey of the 'Productive Ward'. *Int J Nurs Stud*. 2014; 51: 1634-43.
4. Langley GJ, Moen R, Nolan KM, Nolan TW, Norman CL and Provost LP. *The improvement guide: a practical approach to enhancing organizational performance*. John Wiley & Sons, 2009.
5. Baker R, Camosso - Stefinovic J, Gillies C, et al. Tailored interventions to address determinants of practice. *The Cochrane Library*. 2015.
6. Bagai A, Al-Khalidi HR, Sherwood MW, et al. Regional systems of care demonstration project: Mission: Lifeline STEMI Systems Accelerator: Design and methodology. *Am Heart J*. 2014; 167: 15-21.e3.
7. Martin L, Murphy M, Scanlon A, Naismith C, Clark D and Farouque O. Timely treatment for acute myocardial infarction and health outcomes: an integrative review of the literature. *Aust Crit Care*. 2014; 27: 111-8.
8. Piepoli MF, Corrà U, Dendale P, et al. Challenges in secondary prevention after acute myocardial infarction: A call for action. *Eur J Cardiovasc Nurs*. 2017; 16: 369-80.
9. McKee G, Kerins M, Hamilton G, et al. Barriers to ESC guideline implementation: results of a survey from the European Council on Cardiovascular Nursing and Allied Professions (CCNAP). *Eur J Cardiovasc Nurs*. 2017: 1474515117710097.
10. Martilla JA and James JC. Importance-performance analysis. *The journal of marketing*. 1977: 77-9.
11. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012; 33: 2569-619.
12. Aeyels D, Sinnaeve PR, Claeys MJ, et al. Key interventions and quality indicators for quality improvement of STEMI care: a RAND Delphi survey. *Acta Cardiol*. 2017: 1-10.
13. Rickham PP. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. *Br Med J*. 1964; 2: 177.
14. Maddox TM, Albert NM, Borden WB, et al. The Learning Healthcare System and Cardiovascular Care: A Scientific Statement From the American Heart Association. *Circulation*. 2017; 135: e826-e57.
15. American College of Cardiology. The ACC Quality Improvement for Institutions program. Washington, DC2013.
16. Hulscher ME, Schouten LM, Grol RP and Buchan H. Determinants of success of quality improvement collaboratives: what does the literature show? *BMJ quality & safety*. 2013; 22: 19-31.

17. Rademakers J, Delnoij D and de Boer D. Structure, process or outcome: which contributes most to patients' overall assessment of healthcare quality? *BMJ Quality & Safety*. 2011.
18. Bilimoria KY. Facilitating quality improvement: Pushing the pendulum back toward process measures. *JAMA*. 2015; 314: 1333-4.
19. Lodewijckx C, Decramer M, Sermeus W, Panella M, Deneckere S and Vanhaecht K. Eight-step method to build the clinical content of an evidence-based care pathway: the case for COPD exacerbation. *Trials*. 2012; 13: 229.
20. Resar R, Griffin F, Haraden C and Nolan T. Using Care Bundles to Improve Health Care Quality. Cambridge, Massachusetts: Institute for Healthcare Improvement, 2012.
21. Rousseaux C, Mols P, Sinnaeve PR, et al. Mode of admission and its effect on adherence to reperfusion therapy guidelines in Belgian STEMI patients. *European Heart Journal: Acute Cardiovascular Care*. 2016.
22. Jollis JG, Al-Khalidi HR, Roettig ML, et al. Regional Systems of Care Demonstration Project: American Heart Association Mission: Lifeline STEMI Systems Accelerator. *Circulation*. 2016; 134: 365-74.
23. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. *European journal of preventive cardiology*. 2016; 23: 636-48.
24. Resor CD, Nathan A, Kereiakes DJ, et al. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. *Circulation*. 2016; 134: 989-98.
25. Gevaert SA, De Bacquer D, Evrard P, et al. Gender, TIMI risk score and in-hospital mortality in STEMI patients undergoing primary PCI: results from the Belgian STEMI registry. *EuroIntervention*. 2014; 9: 1095-101.
26. Roche TE, Gardner G and Lewis PA. Effectiveness of an emergency nurse practitioner service for adults presenting to rural hospitals with chest pain: protocol for a multicentre, longitudinal nested cohort study. *BMJ open*. 2015; 5: e006997.
27. NICE. Medicines optimisation. The safe and effective use of medicines to enable the best possible outcomes. *NICE Guideline*. National Intsitute for healthcare Improvement, 2015, p. 1-220.
28. Dunlay SM, Alexander KP, Melloni C, et al. Medical records and quality of care in acute coronary syndromes: results from CRUSADE. *Arch Intern Med*. 2008; 168: 1692-8.
29. Sales AE. Reflections on the state of nursing implementation science. *Int J Nurs Stud*. 2013; 50: 443-4.
30. Jaarsma T, Klompstra L, Ski CF and Thompson DR. Preference-based care and research. *Eur J Cardiovasc Nurs*. 2017; 0: 1474515117714349.
31. Boivin A, Lehoux P, Lacombe R, Burgers J and Grol R. Involving patients in setting priorities for healthcare improvement: a cluster randomized trial. *Implement Sci*. 2014; 9: 24.
32. Morrow DA, Antman EM, Charlesworth A, et al. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy. *Circulation*. 2000; 102: 2031-7.

Tables

Table 1. Documentation of patient characteristics based on the STEMI TIMI score by Morrow et al.[32]

Patient characteristics	Documented		Not documented	
	n/N	(%)	n	(%)
Men	224/300	(74.7%)	0	(0.0%)
Weight < 67kg	30/207	(14.5%)	93	(31.0%)
Systolic Blood Pressure < 100	21/270	(7.8%)	30	(10.0%)
Heart rate < 100	265/298	(88.9%)	2	(0.7%)
Arterial Hypertension	140/248	(56.4%)	52	(17.3%)
Diabetes	40/236	(16.9%)	64	(21.3%)
Hyperlipidemia	130/206	(63.1%)	94	(31.3%)
Chronic Kidney Disease	14/201	(6.9%)	99	(33.0%)
Active Smoking	131/246	(53.2%)	54	(18.0%)
Coronary Artery Disease	6/201	(2.9%)	99	(33.0%)
Peripheral Vascular Disease	22/184	(11.9%)	116	(38.7%)
Killip Class	217/300	(72.3%)	83	(27.7%)
1	179/217	(82.4%)		
2	26/217	(11.9%)		
3	5/217	(2.3%)		
4	7/217	(3.2%)		
Reperfusion therapy	290/300	(96.7%)	8	(2.7%)
Primary PCI	288/290	(99.3%)		
Facilitated PCI	1/290	(0.3%)		
Thrombolysis	0/290	(0.0%)		
CABG	1/290	(0.3%)		
Admitted at PCI center	133/300	(44.3%)	0	(0.0%)
Transferred to a PCI center	167/300	(55.7%)	0	(0.0%)
Admitted to an academic center	80/300	(26.7%)	0	(0.0%)

PCI: Percutaneous coronary intervention; CABG: coronary artery bypass graft

Table 2: Overview of STEMI key interventions and descriptive statistics importance and performance.

Rank	Key intervention	Median (%)	IQR (%)		CVI (%)	P-value
1	Performance of smoking cessation	27.3	17.1	42.2	76	0.000
2	Assessment of home medication	20.0	10.0	73.8	79	0.000
3	Assessment of cardiovascular risk factors	72.8	62.5	76.4	91	0.000
4	Performance of nutritional advice	41.2	22.5	85.9	85	0.000
5	Performance of cardiac rehabilitation	50.0	30.0	77.5	79	0.000
6	Reperfusion performed within guideline delays	60.0	44.1	82.1	100	0.000
7	Assessment of cardiovascular antecedents	80.0	38.8	91.3	100	0.000
8	Performance of peri-procedural aspirin	75.0	66.7	90.0	85	0.000
9	Performance of peri-procedural anticoagulation	89.5	62.5	100.0	91	0.000
10	Performance of peri-procedural P2Y12 inhibitor	85.0	74.3	92.5	85	0.372
11	Performance of ACE or ARB at discharge	83.3	72.5	85.0	91	0.000
12	Performance of ECG monitoring	100.0	89.2	100.0	85	0.000
13	Assessment of a 12 lead ECG	85.0	77.5	92.5	100	0.000
14	Performance of betablocking at discharge	88.9	82.1	94.9	85	0.006
15	Performance of left ventricular function evaluation	94.4	88.9	100.0	91	0.001
16	Assessment of systolic blood pressure	95.0	80.0	100.0	97	0.001
17	Reperfusion performed by primary PCI	100.0	100.0	100.0	91	0.654
18	Performance of aspirin at discharge	100.0	92.5	100.0	94	0.056
19	Performance of statin at discharge	100.0	94.1	100.0	91	0.225
20	Performance of P2Y12-inhibitor at discharge	95.0	94.9	100.0	91	0.632
21	Assessment of Killip class	90.0	72.5	100.0	65	0.000
22	Performance of blood tests	75.8	72.5	84.6	56	0.000
23	Performance of peri-procedural opioid	35.0	25.7	48.7	44	0.001

Between-hospital variation was tested by a Kruskal-Wallis test for skewed data distributions within independent samples. Key interventions were ranked by priority for improvement. ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; CVI: content validity index; ECG: electrocardiogram; P2Y12 inhibitor: P2Y12 inhibitors bind to the $P2Y_{12}$ protein receptor that acts as a regulator in blood clotting; PCI: percutaneous coronary intervention.

Figures

Figure 1: Importance-performance analysis of key interventions for in-hospital STEMI care



Quadrant 1: both importance and performance >75%; Quadrant 2: importance > 75%, performance ≤ 75%. Quadrant 3: both importance and performance ≤ 75%; Quadrant 4: importance ≤ 75%, performance > 75¨%; Bubble size represents IQR of between-hospital variation on performance; Key interventions are numbered according to their entrance in Table 2. 1: Performance of smoking cessation; 2: Assessment of home medication; 3: Assessment of cardiovascular risk factors; 4: Performance of nutritional advice; 5: Performance of cardiac rehabilitation; 6: Reperfusion performed within guideline delays; 7: Performance of peri-procedural aspirin; 8: Assessment of cardiovascular antecedents; 9: Performance of peri-procedural anticoagulation; 10: Performance of ACE or ARB at discharge; 11: Performance of peri-procedural P2Y12 inhibitor; 12: Performance of ECG monitoring; 13: Assessment of a 12 lead ECG; 14: Performance of betablocking at discharge; 15: Performance of left ventricular function evaluation; 16: Assessment of systolic blood pressure; 17: Performance of P2Y12-inhibitor at discharge; 18: Performance of aspirin at discharge; 19: Performance of statin at discharge; 20: Reperfusion performed by primary PCI; 21: Assessment of Killip class upon admission; 22: Performance of diagnostic blood tests upon admission; 23: Performance of peri-procedural opioid

Figure 2: Heat-map of per-hospital performance on important STEMI key interventions

			Hospital																
Nr	**Key intervention**	**CVI (%)**	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**	**13**	**14**	**15**	**Median (%)**	**Priority in No. hospitals**
1	Performance of smoking cessation	**76**	20	0	0	25	14	20	33	27	29	89	13	55	40	44	100	**27**	**13**
2	Assessment of home medication	**79**	20	20	5	8	43	10	95	100	18	8	88	60	60	10	90	**20**	**11**
3	Assessment of cardiovascular risk factors	**91**	56	29	66	73	74	33	78	73	68	59	91	72	88	73	91	**73**	**11**
4	Performance of nutritional advice	**85**	11	70	0	20	39	30	42	84	41	90	20	90	25	88	100	**41**	**10**
5	Performance of cardiac rehabilitation	**79**	16	25	56	50	50	75	5	63	47	80	5	95	35	88	100	**50**	**10**
6	Reperfusion performed within guideline delays	**100**	0	42	79	20	69	100	58	71	86	60	46	90	100	53	26	**60**	**10**
7	Performance of peri-procedural aspirin	**85**	70	75	68	80	74	85	10	35	65	45	95	100	95	85	100	**75**	**7**
8	Assessment of cardiovascular history	**100**	48	5	73	100	83	5	30	25	83	80	93	55	100	95	90	**80**	**7**
9	Performance of peri-procedural anticoagulation	**91**	75	45	53	60	89	55	100	100	90	100	100	65	80	95	100	**89**	**5**
10	Performance of ACE or ARB at discharge	**91**	68	70	83	75	83	85	89	95	76	60	85	90	70	75	83	**83**	**4**
11	Performance of peri-procedural P2Y12 inhibitor	**85**	55	75	53	75	74	85	20	95	75	95	85	90	100	90	100	**85**	**4**
12	Performance of ECG monitoring	**85**	100	95	83	0	100	45	100	0	100	100	100	100	95	100	100	**100**	**3**
13	Assessment of a 12 lead ECG	**100**	25	95	90	100	75	85	80	85	75	70	100	100	90	85	85	**85**	**2**
14	Performance of betablocking at discharge	**85**	84	60	94	85	78	95	100	95	88	80	70	95	100	94	89	**89**	**2**
15	Performance of left ventricular function evaluation	**91**	94	100	94	90	100	80	100	89	88	75	70	100	100	100	100	**94**	**1**
16	Assessment of systolic blood pressure	**97**	75	80	80	90	95	100	100	100	75	100	100	70	95	90	100	**95**	**1**
17	Performance of P2Y12-inhibitor at discharge	**91**	89	100	100	95	89	95	95	100	100	95	95	100	100	100	94	**95**	**0**
18	Performance of aspirin at discharge	**94**	84	90	100	100	100	95	100	100	100	90	100	100	100	100	89	**100**	**0**
19	Performance of statin at discharge	**91**	89	90	100	100	94	95	100	100	100	85	100	100	100	94	94	**100**	**0**
20	Reperfusion performed by primary PCI	**91**	100	100	95	95	95	100	100	100	100	100	100	100	100	100	100	**100**	**0**
	Overall performance of key interventions (%)		**56**	**63**	**68**	**67**	**76**	**65**	**71**	**76**	**75**	**75**	**77**	**82**	**82**	**80**	**89**		
	No. of priority key interventions		**11**	**10**	**9**	**8**	**8**	**7**	**7**	**7**	**6**	**6**	**6**	**6**	**5**	**4**	**1**		

Performance cut-points were set at ≤ 75% (red); >75% (yellow) <95%; ≥ 95% (green). Key interventions are numbered according to their entrance in Table 2. 1: Performance of smoking cessation; 2: Assessment of home medication; 3: Assessment of cardiovascular risk factors; 4: Performance of nutritional advice; 5: Performance of cardiac rehabilitation; 6: Reperfusion performed within guideline delays; 7: Performance of peri-procedural aspirin; 8: Assessment of cardiovascular antecedents; 9: Performance of peri-procedural anticoagulation; 10: Performance of ACE or ARB at discharge; 11: Performance of peri-procedural P2Y12 inhibitor; 12: Performance of ECG monitoring; 13: Assessment of a 12 lead ECG; 14: Performance of betablocking at discharge; 15: Performance of left ventricular function evaluation; 16: Assessment of systolic blood pressure; 17: Performance of P2Y12-inhibitor at discharge; 18: Performance of aspirin at discharge; 19: Performance of statin at discharge; 20: Reperfusion performed by primary PCI; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; CVI: content validity index; ECG: electrocardiogram; P2Y12 inhibitor: P2Y12 inhibitors bind to the $P2Y_{12}$ protein receptor that acts as a regulator in blood clotting; PCI: percutaneous coronary intervention.